Last reviewed · How we verify
Dexmedetomidine load
Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care settings, Procedural sedation in perioperative and diagnostic settings.
At a glance
| Generic name | Dexmedetomidine load |
|---|---|
| Also known as | Precedex, Dexmedetomidine Hydrochloride |
| Sponsor | University of Pennsylvania |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, resulting in decreased norepinephrine release and subsequent sedation. This mechanism also provides analgesic and anxiolytic effects while maintaining a unique 'cooperative sedation' profile where patients remain arousable. The drug is the active d-enantiomer of medetomidine and has a rapid onset and short duration of action.
Approved indications
- Sedation of intubated and mechanically ventilated patients in intensive care settings
- Procedural sedation in perioperative and diagnostic settings
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Tachycardia (rebound)
Key clinical trials
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery (PHASE4)
- Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial) (PHASE2)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Comparison Between Total Intravenous Anesthesia With Magnesium Sulphate Versus Total Intravenous Anesthesia With Dexmedetomidine in Patients Undergoing Lumbar Spine Surgeries (PHASE3)
- Attenuate the Stress Response in Laparoscopic Cholecystectomy (PHASE4)
- General Anesthesia Versus Sedation By Dexmedetomidine and Ketamine With Local Infiltration for Percutaneous Transcatheter Closure of Atrial Septal Defect in Pediatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine load CI brief — competitive landscape report
- Dexmedetomidine load updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI